Drug–drug interactions in patients receiving hematopoietic stem cell transplantation

Pejčić, Ana V; Janković, Slobodan M.; Opančina, Valentina; Babić, Goran; Milosavljević, Miloš N.

doi:10.1080/17425255.2019.1552256

Cited by 11 publications

(10 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, it was reported that foscarnet, an antiviral option in immunocompromised patients, has the risk of causing seizure activity (54). It is noteworthy that drug-drug interaction during the process of HSCT should not be overlooked by prescribers as this phenomenon is related to increasing occurrence of adverse consequences (55,56). Take the combination of CNIs and azole antifungals for an example, the latter obviously increases the plasma concentration of CsA and the incidence of epileptiform seizures due to potent inhibition of CYP 3A4 (55)(56)(57).…”

Section: Other Drugsmentioning

confidence: 99%

Epileptic Seizures After Allogeneic Hematopoietic Stem Cell Transplantation

2021

View full text Add to dashboard Cite

Technique in allogeneic hematopoietic stem cell transplantation has greatly advanced over the past decades, which has led to an increase in the number of patients receiving transplantation, but the complex procedure places these transplant recipients at high risk of a large spectrum of complications including neurologic involvement. As a common manifestation of neurological disorders, epileptic seizures after transplantation have been of great concern to clinicians because it seriously affects the survival rate and living quality of those recipients. The aim of this review is to elucidate the incidence of seizures after allogeneic hematopoietic stem cell transplantation, and to further summarize in detail its etiologies, possible mechanisms, clinical manifestations, therapeutic schedule, and prognosis, hoping to improve doctors' understandings of concurrent seizures following transplantation, so they can prevent, process, and eventually improve the survival and outlook for patients in a timely manner and correctly.

show abstract

Section: Other Drugsmentioning

confidence: 99%

Epileptic Seizures After Allogeneic Hematopoietic Stem Cell Transplantation

2021

View full text Add to dashboard Cite

show abstract

“…It should alert clinicians not to indulge the promising results of novel anti-tumor therapies but also consider their side effects. DDI have constantly played a role in medical therapy also affecting hematology patients in the context of immunosuppressive agents, anti-infective drugs, and proton-pump inhibitors [46,47].…”

Section: Drug-drug Interactions and Therapeutic Drug Monitoringmentioning

confidence: 99%

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma

et al. 2020

View full text Add to dashboard Cite

With the advent of new targeted drugs in hematology and oncology patient prognosis is improved. Combination with antifungal prophylaxis challenges clinicians due to pharmacological profiles prone to drug–drug interactions (DDI). Midostaurin is a novel agent for FLT3-TKD/-ITDmut-acute myeloid leukemia (AML) and metabolized via cytochrome P450 3A4 (CYP3A4). Posaconazole is a standard of care antifungal agent used for prophylaxis during induction treatment of AML and a strong CYP3A4 inhibitor. Concomitant administration of both drugs leads to elevated midostaurin exposure. Both drugs improve overall survival at low numbers needed to treat. The impact of CYP3A4-related DDI remains to be determined. Severe adverse events have been observed; however, it remains unclear if they can be directly linked to DDI. The lack of prospective clinical studies assessing incidence of invasive fungal infections and clinical impact of DDI contributes to neglecting live-saving antifungal prophylaxis. Management strategies to combine both drugs have been proposed, but evidence on which approach to use is scarce. In this review, we discuss several approaches in the specific clinical setting of concomitant administration of midostaurin and posaconazole and give examples from everyday clinical practice. Therapeutic drug monitoring will become increasingly important to individualize and personalize antineoplastic concomitant and antifungal treatment in the context of DDI. Pharmaceutical companies addressing the issue in clinical trials may take a pioneer role in this field. Other recently developed and approved drugs for the treatment of AML likely inhere potential of DDI marking a foreseeable issue in future treatment of this life-threatening disease.

show abstract

“…Vorikonazolle bu tür etkileşimler genellikle iki yönlüdür (26). Azollerin yaygın ve klinik olarak önemli ilaç etkileşimleri Tablo 3'te özetlenmiştir (9,13,(25)(26)(27)(29)(30)(31)(32)(33)(34)(35).…”

Section: Azollerin İlaç Etkileşimleriunclassified

Challenges in Antifungal Therapy: Therapeutic Drug Monitoring, Drug-Drug Interactions and Approach to Failure After Primary Therapy

Memisoglu¹

2020

Klimik Dergisi

View full text Add to dashboard Cite

show abstract

Drug–drug interactions in patients receiving hematopoietic stem cell transplantation

Cited by 11 publications

References 82 publications

Epileptic Seizures After Allogeneic Hematopoietic Stem Cell Transplantation

Epileptic Seizures After Allogeneic Hematopoietic Stem Cell Transplantation

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma

Challenges in Antifungal Therapy: Therapeutic Drug Monitoring, Drug-Drug Interactions and Approach to Failure After Primary Therapy

Contact Info

Product

Resources

About